Once again, the Frankfurt-based cannabis company Cansativa makes headlines. After becoming the first German company to receive the authorization to import medical cannabis from South America in April, Cansativa further extends its regular supplier base to Australian company Little Green Pharma.
“Our new partner in Australia helps us to tackle the growing supply problems in the German market and secure the amount of deliveries necessary to meet the increasing demands by the patients. This is an important step in ensuring security of supply for patients in Germany.”
Benedikt Sons, co-founder of Cansativa and co-managing director together with Jakob Sons.
Following its legalization of medical cannabis in 2017, Germany has become one of the fastest growing markets in Europe. Cansativa is eager to professionalize the market through service for foreign companies along the value chain, starting with imports to Europe and Germany. This also applies to storage and purchase, making Cansativa an increasingly important player in the German and European cannabis trade.
“Cansativa has aggregated a lot of know-how over the last year regarding process reliability, dealing with authorities, market structure, competition, and the necessary legal expertise. Just recently we successfully imported our first samples from Uruguay. With the Australian import, we once again underscore our ambition to provide security of supply through global sourcing. As a first mover of the whole industry, we make our contribution to a more professional and reliable market,” concludes Benedikt Sons.
“We are thrilled to work on this proof of concept and that the first Australian products will soon touch European soil. Together with Cansativa we are about to finalize the supplier qualification for the European market.”
Fleta Solomon, managing director of LGP.